Ovid Therapeutics IncNASDAQ:OVID
- LAST PRICE3.1500
- TODAY'S CHANGE (%)-0.1250 (-3.8168%)
- Bid / Lots3.0200/ 1
- Ask / Lots3.3900/ 15
- Open / Previous Close3.3000 / 3.2750
- Day Range
- 52 Week Range
- Volume88,874
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OVID |
|---|---|---|
| 09:32 ET | 12524 | 3.2606 |
| 09:38 ET | 399 | 3.261 |
| 10:03 ET | 127 | 3.305 |
| 10:14 ET | 3639 | 3.26 |
| 10:17 ET | 1400 | 3.26 |
| 10:42 ET | 6049 | 3.21 |
| 10:57 ET | 1000 | 3.21 |
| 11:00 ET | 600 | 3.21 |
| 11:11 ET | 1426 | 3.18 |
| 11:15 ET | 1673 | 3.182 |
| 11:24 ET | 2486 | 3.152 |
| 11:27 ET | 200 | 3.15 |
| 11:45 ET | 100 | 3.15 |
| 11:49 ET | 100 | 3.15 |
| 12:00 ET | 100 | 3.15 |
| 12:02 ET | 100 | 3.145 |
| 12:05 ET | 1171 | 3.165 |
| 12:18 ET | 339 | 3.1666 |
| 12:36 ET | 400 | 3.17 |
| 12:39 ET | 100 | 3.175 |
| 12:43 ET | 132 | 3.171 |
| 12:50 ET | 149 | 3.17 |
| 01:12 ET | 100 | 3.17 |
| 01:17 ET | 100 | 3.17 |
| 01:24 ET | 200 | 3.17 |
| 01:30 ET | 1156 | 3.17 |
| 01:32 ET | 252 | 3.17 |
| 01:33 ET | 426 | 3.1614 |
| 01:44 ET | 229 | 3.16 |
| 01:55 ET | 1000 | 3.1688 |
| 02:00 ET | 100 | 3.15 |
| 02:02 ET | 100 | 3.15 |
| 02:11 ET | 100 | 3.15 |
| 02:27 ET | 350 | 3.14 |
| 02:44 ET | 100 | 3.12 |
| 02:49 ET | 100 | 3.121 |
| 02:58 ET | 100 | 3.121 |
| 03:02 ET | 200 | 3.12 |
| 03:03 ET | 600 | 3.13 |
| 03:05 ET | 600 | 3.13 |
| 03:12 ET | 1400 | 3.12 |
| 03:16 ET | 300 | 3.11 |
| 03:18 ET | 200 | 3.11 |
| 03:21 ET | 12215 | 3.135 |
| 03:23 ET | 250 | 3.16 |
| 03:30 ET | 100 | 3.141 |
| 03:32 ET | 200 | 3.15 |
| 03:36 ET | 300 | 3.14 |
| 03:38 ET | 100 | 3.15 |
| 03:39 ET | 100 | 3.15 |
| 03:41 ET | 100 | 3.14 |
| 03:43 ET | 400 | 3.15 |
| 03:45 ET | 251 | 3.15 |
| 03:48 ET | 100 | 3.14 |
| 03:50 ET | 555 | 3.15 |
| 03:52 ET | 100 | 3.14 |
| 03:56 ET | 100 | 3.15 |
| 03:57 ET | 100 | 3.15 |
| 03:59 ET | 536 | 3.15 |
May 16, 2024
DJ Ovid Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co., from 7:17AM ET on Thursday May 16, 2024 by Dow Jones
7:17AM ET on Thursday May 16, 2024 by Dow Jones
May 14, 2024
*DJ Ovid Therapeutics 1Q Loss/Shr 17c >OVID, from 8:00AM ET on Tuesday May 14, 2024 by Dow Jones
8:00AM ET on Tuesday May 14, 2024 by Dow JonesOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results, from 8:00AM ET on Tuesday May 14, 2024 by Dow Jones
8:00AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, from 7:00AM ET on Monday May 13, 2024 by Dow Jones
7:00AM ET on Monday May 13, 2024 by Dow Jones
May 7, 2024
DJ Ovid Therapeutics Is Maintained at Neutral by Citigroup, from 1:51PM ET on Tuesday May 07, 2024 by Dow Jones
1:51PM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ovid Therapeutics Inc | 223.1M | -4.4x | --- |
Merrimack Pharmaceuticals Inc | 223.7M | -183.2x | --- |
Compass Therapeutics Inc. | 220.1M | -4.6x | --- |
Prelude Therapeutics Inc | 219.7M | -2.1x | --- |
Acumen Pharmaceuticals Inc | 219.3M | -3.5x | --- |
INmune Bio Inc | 214.6M | -5.7x | --- |
Company Information
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Contact Information
- Headquarters
- 441 NINTH AVENUE, 14TH FLOORNEW YORK, NY, United States 10001
- Phone
- 212-776-4381
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Jeremy Levin
- Chief Business and Financial Officer
- Jeffrey Rona
- Chief Operating Officer
- Jason Tardio
- Chief Scientific Officer
- Zhong Zhong
- Chief Compliance Officer, General Counsel, Corporate Secretary
- Thomas Perone
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $223.1M |
|---|---|
Revenue (TTM) | $473.5K |
Shares Outstanding | 70.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.59 |
EPS | $-0.72 |
Book Value | $1.24 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | 471.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13,052.22% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
